

Docosahexaenoic acid for the reduction of bronchopulmonary dysplasia in preterm infants born at less than 29 weeks gestational age: a randomised controlled trial. The N3RO trial.

STATISTICAL ANALYSIS PLAN

**For access please contact Health Translation SA
enquiries@healthtranslationsa.org.au**